About: Motavizumab     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/c/8XJhMtTPmL

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.

AttributesValues
rdf:type
rdfs:label
  • موتافيزوماب (ar)
  • Motavizumab (en)
rdfs:comment
  • موتافيزوماب هو جسم مضاد وحيد النسيلة مأنسن طورته (تتبع حالياً) لمنع عدوى فيروس الجهاز التنفسي المخلوي في الرضع المعرضين لخطر مرتفع الشدة. (ar)
  • Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials. (en)
dct:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
ATC suffix
  • BD02 (en)
ATC prefix
  • J06 (en)
c
CAS number
ChemSpiderID
  • none (en)
DrugBank
  • DB06310 (en)
H
KEGG
  • D06621 (en)
n
O
routes of administration
s
source
  • zu/o (en)
target
  • RSV glycoprotein F (en)
tradename
  • Numax (en)
type
  • mab (en)
UNII
Verifiedfields
  • changed (en)
verifiedrevid
Watchedfields
  • changed (en)
has abstract
  • موتافيزوماب هو جسم مضاد وحيد النسيلة مأنسن طورته (تتبع حالياً) لمنع عدوى فيروس الجهاز التنفسي المخلوي في الرضع المعرضين لخطر مرتفع الشدة. (ar)
  • Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials. In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab. In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV. (en)
mab type
  • mab (en)
protein bound
  • None (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
alternative name
  • Numax (en)
CAS number
  • 677010-34-3
DrugBank
  • DB06310
FDA UNII code
  • 50Y163LK8Q
KEGG
  • D06621
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git147 as of Sep 06 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3331 as of Sep 2 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 52 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software